Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024.
作者信息
Xie Yan, Choi Taeyoung, Al-Aly Ziyad
机构信息
Clinical Epidemiology Center, VA St Louis Health Care System, St Louis, Missouri.
出版信息
JAMA. 2024 Jun 11;331(22):1963-1965. doi: 10.1001/jama.2024.7395.
Abstract
摘要
相似文献
1
Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024.2023 - 2024年秋冬因新冠病毒感染（COVID - 19）与流感住院患者的死亡率
JAMA. 2024 Jun 11;331(22):1963-1965. doi: 10.1001/jama.2024.7395.
2
Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023.2022 - 2023年秋冬因新冠病毒病住院患者与季节性流感患者的死亡风险
JAMA. 2023 May 16;329(19):1697-1699. doi: 10.1001/jama.2023.5348.
3
Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study.新冠肺炎与季节性流感住院患者临床表现及死亡风险的比较评估：队列研究
BMJ. 2020 Dec 15;371:m4677. doi: 10.1136/bmj.m4677.
4
Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study.比较 COVID-19 和季节性流感的特征、发病率和死亡率：一项全国性、基于人群的回顾性队列研究。
Lancet Respir Med. 2021 Mar;9(3):251-259. doi: 10.1016/S2213-2600(20)30527-0. Epub 2020 Dec 17.
5
COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries.COVID-19 患者中的自身免疫性疾病：三个国家多国队列网络中的特征和结局。
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI37-SI50. doi: 10.1093/rheumatology/keab250.
6
Outcomes of SARS-CoV-2 and Seasonal Viruses Among 2 Million Adults Hospitalized for Severe Acute Respiratory Infection During the COVID-19 Pandemic in Brazil.在 COVID-19 大流行期间巴西 200 万例因严重急性呼吸道感染住院的成年人中，SARS-CoV-2 和季节性病毒的结局。
J Infect Dis. 2024 Oct 16;230(4):868-877. doi: 10.1093/infdis/jiae295.
7
Clinical outcomes and characteristics of patients hospitalized for Influenza or COVID-19 in Germany.德国因流感或 COVID-19 住院患者的临床结局和特征。
Int J Infect Dis. 2021 Feb;103:316-322. doi: 10.1016/j.ijid.2020.11.204. Epub 2020 Dec 31.
8
Outcomes of COVID-19 and Influenza in Cerebral Palsy Patients Hospitalized in the United States: Comparative Study of a Nationwide Database.美国住院脑瘫患者 COVID-19 和流感的结局：全国范围内数据库的比较研究。
Viruses. 2024 Aug 12;16(8):1284. doi: 10.3390/v16081284.
9
Comparison of Clinical Features and Outcomes in Critically Ill Patients Hospitalized with COVID-19 versus Influenza.比较 COVID-19 与流感住院危重症患者的临床特征和结局。
Ann Am Thorac Soc. 2021 Apr;18(4):632-640. doi: 10.1513/AnnalsATS.202007-805OC.
10
Laboratory-Confirmed Influenza-Associated Hospitalizations Among Children and Adults - Influenza Hospitalization Surveillance Network, United States, 2010-2023.实验室确诊的儿童和成人流感相关住院病例 - 流感住院监测网络，美国，2010-2023 年。
MMWR Surveill Summ. 2024 Oct 31;73(6):1-18. doi: 10.15585/mmwr.ss7706a1.
引用本文的文献
1
Influenza A vs. COVID-19: A Retrospective Comparison of Hospitalized Patients in a Post-Pandemic Setting.甲型流感与新冠病毒：大流行后环境下住院患者的回顾性比较
Microorganisms. 2025 Aug 6;13(8):1836. doi: 10.3390/microorganisms13081836.
2
An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.一种RBD-Fc黏膜疫苗为小鼠和仓鼠提供了针对SARS-CoV-2的变异体抗性保护。
NPJ Vaccines. 2025 May 18;10(1):100. doi: 10.1038/s41541-025-01155-4.
3
Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review.恩西他韦作为轻至中度新型冠状病毒肺炎的一种新型治疗选择：一篇叙述性文献综述
Ther Adv Infect Dis. 2025 Apr 11;12:20499361251321724. doi: 10.1177/20499361251321724. eCollection 2025 Jan-Dec.
4
Rates of Hospitalization and Death due to COVID-19 in US Veterans With SARS-CoV-2 Infection in the XBB-, JN.1-, and KP-Predominant Eras.在美国XBB、JN.1和KP毒株占主导时期感染SARS-CoV-2的退伍军人中，因COVID-19住院和死亡的比率。
Open Forum Infect Dis. 2025 Mar 10;12(3):ofaf115. doi: 10.1093/ofid/ofaf115. eCollection 2025 Mar.
5
Effect of pulmonary rehabilitation for patients with long COVID-19: a systematic review and meta-analysis of randomized controlled trials.新冠肺炎长期患者的肺康复效果：随机对照试验的系统评价和荟萃分析
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251323482. doi: 10.1177/17534666251323482. Epub 2025 Mar 13.
6
Biomarker states and risk of death among individuals hospitalized with SARS-CoV-2 infection.感染新型冠状病毒2（SARS-CoV-2）的住院患者的生物标志物状态与死亡风险
BMC Infect Dis. 2025 Feb 24;25(1):260. doi: 10.1186/s12879-025-10651-w.
7
The evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance.新冠病毒疾病（COVID-19）的演变态势：与JN.1亚变体主导的2023 - 2024阶段住院COVID-19相关死亡率相关的因素
BMC Infect Dis. 2025 Jan 27;25(1):130. doi: 10.1186/s12879-025-10480-x.
8
Immune-Boosting and Antiviral Effects of Antioxidants in COVID-19 Pneumonia: A Therapeutic Perspective.抗氧化剂在新冠肺炎肺炎中的免疫增强和抗病毒作用：治疗视角
Life (Basel). 2025 Jan 16;15(1):113. doi: 10.3390/life15010113.
9
New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons.西班牙新冠疫苗接种新建议：为下一季优化。
Enferm Infecc Microbiol Clin. 2025 Jan;43(1):36-46. doi: 10.1016/j.eimc.2024.08.012.
10
Demographic trends and disparities in mortality related to coexisting heart failure and diabetes mellitus among older adults in the United States between 1999 and 2020: A retrospective population-based cohort study from the CDC WONDER database.1999年至2020年美国老年人中心力衰竭与糖尿病并存相关的人口趋势及死亡率差异：一项基于疾病预防控制中心WONDER数据库的回顾性队列研究。
Int J Cardiol Cardiovasc Risk Prev. 2024 Aug 24;23:200326. doi: 10.1016/j.ijcrp.2024.200326. eCollection 2024 Dec.
Zotero 插件